Clinicopathological analysis of hepatic immune-related adverse events in comparison with autoimmune hepatitis and graft-versus host disease.
Adult
Aged
Aged, 80 and over
Antigens, CD20
/ immunology
CD4-Positive T-Lymphocytes
/ immunology
CD8-Positive T-Lymphocytes
/ immunology
Female
Graft vs Host Disease
/ chemically induced
Hepatitis, Autoimmune
/ etiology
Humans
Immune Checkpoint Inhibitors
/ adverse effects
Liver
/ drug effects
Male
Middle Aged
Neoplasms
/ drug therapy
T-Lymphocytes, Regulatory
/ immunology
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
29 04 2021
29 04 2021
Historique:
received:
25
11
2020
accepted:
16
04
2021
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
9
11
2021
Statut:
epublish
Résumé
Immune checkpoint inhibitors (ICIs) targeting programmed cell death 1 (PD-1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) are widely used to treat advanced metastatic cancers. Neutralisation of PD-1 or CTLA-4 by ICIs results in immune-related adverse events (irAEs). The clinicopathological features of twelve patients with hepatic irAEs were evaluated and compared to those of ten patients with autoimmune hepatitis (AIH) or graft-versus-host disease (GVHD). No significant difference was seen in serum levels of transaminases, whereas serum levels of IgG and anti-nuclear antibody were higher in patients with AIH than in those with GVHD or hepatic irAEs. Inflammation was limited to the liver lobes in patients with GVHD or hepatic irAEs, whereas patients with AIH exhibited both portal and lobular inflammation. Immunohistochemical analyses revealed a predominant infiltration of CD8
Identifiants
pubmed: 33927311
doi: 10.1038/s41598-021-88824-1
pii: 10.1038/s41598-021-88824-1
pmc: PMC8085223
doi:
Substances chimiques
Antigens, CD20
0
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
9242Références
Mod Pathol. 2018 Jun;31(6):965-973
pubmed: 29403081
J Immunol. 2005 Mar 1;174(5):3051-8
pubmed: 15728519
Mod Pathol. 2021 Feb;34(2):426-437
pubmed: 32884128
J Immunol. 2012 Jan 15;188(2):724-34
pubmed: 22156590
Gastroenterology. 2011 Apr;140(4):1322-1333.e1-5
pubmed: 21237169
J Clin Oncol. 2015 Jun 10;33(17):1974-82
pubmed: 25605845
J Immunol Res. 2019 Nov 25;2019:9437043
pubmed: 31886312
Front Immunol. 2019 Apr 30;10:946
pubmed: 31114585
Sci Transl Med. 2013 Apr 3;5(179):179ra43
pubmed: 23552371
J Clin Invest. 2006 Jun;116(6):1713-22
pubmed: 16741580
J Immunol. 2017 May 15;198(10):3886-3896
pubmed: 28373582
J Hepatol. 2012 Jul;57(1):125-32
pubmed: 22425700
PLoS One. 2017 Jul 11;12(7):e0181107
pubmed: 28700730
Hepatol Commun. 2018 Aug 06;2(8):968-981
pubmed: 30094407
J Hepatol. 2014 Nov;61(5):1106-14
pubmed: 24882050
JAMA Oncol. 2016 Oct 1;2(10):1346-1353
pubmed: 27367787
Bone Marrow Transplant. 2018 Nov;53(11):1401-1415
pubmed: 29872128
Nat Rev Immunol. 2020 Jan;20(1):25-39
pubmed: 31570880
Semin Liver Dis. 2018 Nov;38(4):366-378
pubmed: 30357774
Annu Rev Immunol. 2020 Apr 26;38:541-566
pubmed: 32017635
Trends Immunol. 2004 Nov;25(11):590-4
pubmed: 15489187
Medicine (Baltimore). 2018 Aug;97(33):e11936
pubmed: 30113497
Nat Immunol. 2007 Mar;8(3):277-84
pubmed: 17220892
Trends Immunol. 2020 Jan;41(1):77-91
pubmed: 31791718
Nat Rev Clin Oncol. 2019 Sep;16(9):563-580
pubmed: 31092901
Nat Rev Clin Oncol. 2019 Jun;16(6):356-371
pubmed: 30705439
Curr Opin Pediatr. 2013 Dec;25(6):708-14
pubmed: 24240290
Mucosal Immunol. 2016 Sep;9(5):1234-49
pubmed: 26813347
Nat Med. 2005 Dec;11(12):1299-305
pubmed: 16288282
J Hepatol. 2018 Jun;68(6):1181-1190
pubmed: 29427729
Front Immunol. 2018 Dec 21;9:3061
pubmed: 30622541
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
Future Sci OA. 2018 Oct 04;4(10):FSO341
pubmed: 30457576
J Hepatol. 1999 Nov;31(5):929-38
pubmed: 10580593
Oncol Res Treat. 2018;41(5):272-280
pubmed: 29705787
Blood. 2017 Apr 13;129(15):2186-2197
pubmed: 28151427
Cancer Res. 2016 Sep 15;76(18):5288-301
pubmed: 27503925